drugset / Trial / NCT01217632
A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection
RandomizedParallel-groupDouble-blindTreatment
Summary
The overall goal of this trial is to evaluate the efficacy of FG-3019 for reversing liver fibrosis in subjects with chronic hepatitis B infection who are beginning antiviral therapy with entecavir. This Phase 2 randomized, double-blind, placebo controlled study will enroll subjects with chronic active hepatitis B infection and liver fibrosis (Ishak score ≥2) who are eligible for antiviral therapy.
Timeline
- Start
- 2010-08
- Primary completion
- 2015-06
- Completion
- 2015-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pamrevlumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Pamrevlumab | Monoclonal antibody | 45 mg/kg | Intravenous |
| Background | Entecavir | Small molecule | — | — |